VTYX Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Zacks Investment Research - Mentions: NVO ADMA ARQT

VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know

13 days ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

13 days ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

23 days ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

a month ago - By: Benzinga

Why Ventyx (VTYX) Shares Soared 86.5% After Hours?

4 months ago - By: The Motley Fool

Ventyx (VTYX) Q2 Net Loss Drops 16%

a month ago - By: Benzinga - Mentions: STM AAL SMPL GTX ...

Crude Oil Surges 5%; American Airlines Shares Jump After Q3 Results

a month ago - By: Stocktwits

Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study

a month ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

a month ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

3 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

6 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

7 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

8 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

9 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

10 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

11 months ago - By: Ventyx Biosciences, Inc.

VENTYX BIOSCIENCES INC (VTYX) Stock News

VTYX Latest News, Press Relases and Analysis

VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Why Ventyx (VTYX) Shares Soared 86.5% After Hours?

Ventyx (VTYX) Q2 Net Loss Drops 16%

Crude Oil Surges 5%; American Airlines Shares Jump After Q3 Results

Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio